vs

Side-by-side financial comparison of BICYCLE THERAPEUTICS PLC (BCYC) and Honest Company, Inc. (HNST). Click either name above to swap in a different company.

Honest Company, Inc. is the larger business by last-quarter revenue ($78.1M vs $48.0M, roughly 1.6× BICYCLE THERAPEUTICS PLC). On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs -19.7%). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs -8.4%).

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

The Honest Company, Inc. is an American digital-first consumer goods company, based in Los Angeles and founded by actress Jessica Alba, Christopher Gavigan, and Brian Lee. The company had $319 million in 2021 sales, and was valued at roughly $550 million as of February 2022. Carla Vernón, Chief Executive Officer, is one of the first Afro-Latina CEOs of a U.S. publicly traded company. The Honest Company has raised multiple rounds of venture capital, and went public via an initial public offeri...

BCYC vs HNST — Head-to-Head

Bigger by revenue
HNST
HNST
1.6× larger
HNST
$78.1M
$48.0M
BCYC
Growing faster (revenue YoY)
BCYC
BCYC
+1213.0% gap
BCYC
1193.3%
-19.7%
HNST
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
-8.4%
HNST

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BCYC
BCYC
HNST
HNST
Revenue
$48.0M
$78.1M
Net Profit
$-20.2M
Gross Margin
42.6%
Operating Margin
-51.5%
56.6%
Net Margin
-42.0%
Revenue YoY
1193.3%
-19.7%
Net Profit YoY
61.1%
EPS (diluted)
$-0.29
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCYC
BCYC
HNST
HNST
Q1 26
$78.1M
Q4 25
$48.0M
$88.0M
Q3 25
$11.7M
$92.6M
Q2 25
$2.9M
$93.5M
Q1 25
$10.0M
$97.3M
Q4 24
$3.7M
$99.8M
Q3 24
$2.7M
$99.2M
Q2 24
$9.4M
$93.0M
Net Profit
BCYC
BCYC
HNST
HNST
Q1 26
Q4 25
$-20.2M
$-23.6M
Q3 25
$-59.1M
$758.0K
Q2 25
$-79.0M
$3.9M
Q1 25
$-60.8M
$3.3M
Q4 24
$-809.0K
Q3 24
$-50.8M
$165.0K
Q2 24
$-39.8M
$-4.1M
Gross Margin
BCYC
BCYC
HNST
HNST
Q1 26
42.6%
Q4 25
15.7%
Q3 25
37.3%
Q2 25
40.4%
Q1 25
38.7%
Q4 24
38.8%
Q3 24
38.7%
Q2 24
38.3%
Operating Margin
BCYC
BCYC
HNST
HNST
Q1 26
56.6%
Q4 25
-51.5%
-27.5%
Q3 25
-558.6%
0.3%
Q2 25
-2965.8%
3.1%
Q1 25
-703.7%
2.6%
Q4 24
-1.0%
Q3 24
-2385.9%
0.1%
Q2 24
-498.3%
-4.3%
Net Margin
BCYC
BCYC
HNST
HNST
Q1 26
Q4 25
-42.0%
-26.8%
Q3 25
-503.7%
0.8%
Q2 25
-2703.8%
4.1%
Q1 25
-608.9%
3.3%
Q4 24
-0.8%
Q3 24
-1898.4%
0.2%
Q2 24
-425.3%
-4.4%
EPS (diluted)
BCYC
BCYC
HNST
HNST
Q1 26
$0.00
Q4 25
$-0.29
$-0.21
Q3 25
$-0.85
$0.01
Q2 25
$-1.14
$0.03
Q1 25
$-0.88
$0.03
Q4 24
$-0.01
Q3 24
$-0.74
$0.00
Q2 24
$-0.77
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCYC
BCYC
HNST
HNST
Cash + ST InvestmentsLiquidity on hand
$628.1M
$90.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$610.0M
$169.1M
Total Assets
$717.6M
$214.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCYC
BCYC
HNST
HNST
Q1 26
$90.4M
Q4 25
$628.1M
$89.6M
Q3 25
$648.3M
$71.5M
Q2 25
$721.5M
$72.1M
Q1 25
$793.0M
$72.8M
Q4 24
$879.5M
$75.4M
Q3 24
$890.9M
$53.4M
Q2 24
$961.4M
$36.6M
Total Debt
BCYC
BCYC
HNST
HNST
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$30.9M
Stockholders' Equity
BCYC
BCYC
HNST
HNST
Q1 26
$169.1M
Q4 25
$610.0M
$169.7M
Q3 25
$618.5M
$190.2M
Q2 25
$668.9M
$187.0M
Q1 25
$740.3M
$180.4M
Q4 24
$793.1M
$174.3M
Q3 24
$831.0M
$133.9M
Q2 24
$873.8M
$129.7M
Total Assets
BCYC
BCYC
HNST
HNST
Q1 26
$214.9M
Q4 25
$717.6M
$225.4M
Q3 25
$764.0M
$241.5M
Q2 25
$832.2M
$249.0M
Q1 25
$883.9M
$265.3M
Q4 24
$956.9M
$247.4M
Q3 24
$996.7M
$209.2M
Q2 24
$1.1B
$200.2M
Debt / Equity
BCYC
BCYC
HNST
HNST
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCYC
BCYC
HNST
HNST
Operating Cash FlowLast quarter
$-19.3M
Free Cash FlowOCF − Capex
$-19.9M
FCF MarginFCF / Revenue
-41.5%
Capex IntensityCapex / Revenue
1.2%
0.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-252.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCYC
BCYC
HNST
HNST
Q1 26
Q4 25
$-19.3M
$19.3M
Q3 25
$-71.2M
$-504.0K
Q2 25
$-72.8M
$-745.0K
Q1 25
$-86.4M
$-2.9M
Q4 24
$-164.7M
$-16.8M
Q3 24
$-39.8M
$15.1M
Q2 24
$-44.6M
$2.9M
Free Cash Flow
BCYC
BCYC
HNST
HNST
Q1 26
Q4 25
$-19.9M
$18.1M
Q3 25
$-71.8M
$-624.0K
Q2 25
$-73.3M
$-826.0K
Q1 25
$-87.0M
$-3.0M
Q4 24
$-166.0M
$-17.2M
Q3 24
$-40.3M
$15.0M
Q2 24
$-45.0M
$2.9M
FCF Margin
BCYC
BCYC
HNST
HNST
Q1 26
Q4 25
-41.5%
20.5%
Q3 25
-612.3%
-0.7%
Q2 25
-2509.7%
-0.9%
Q1 25
-871.7%
-3.1%
Q4 24
-4475.7%
-17.2%
Q3 24
-1504.7%
15.1%
Q2 24
-481.2%
3.1%
Capex Intensity
BCYC
BCYC
HNST
HNST
Q1 26
0.6%
Q4 25
1.2%
1.4%
Q3 25
5.7%
0.1%
Q2 25
17.1%
0.1%
Q1 25
6.1%
0.1%
Q4 24
33.3%
0.3%
Q3 24
16.3%
0.1%
Q2 24
4.5%
0.0%
Cash Conversion
BCYC
BCYC
HNST
HNST
Q1 26
Q4 25
Q3 25
-0.66×
Q2 25
-0.19×
Q1 25
-0.90×
Q4 24
Q3 24
91.42×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons